Beyond multidrug-resistant tuberculosis in Europe: a TBNET study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe. We evaluated second-line drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrug-resistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Int. J. Tuberc. Lung Dis.

Title: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Publisher: International Union Against Tuberculosis and Lung Disease

ISSN (Electronic): 1815-7920

ISSN (Print): 1027-3719

Publication date (Electronic): Dec 2015

Volume: 19

Issue: 12

Affiliations

[1 ] Division of Clinical Infectious Diseases and German Center for Infection Research Tuberculosis Unit, Research Center Borstel, Borstel, Germany; Department of Medicine, University of Namibia School of Medicine, Windhoek, Namibia.

[2 ] Department of Global Health, Academic Medical Center, University of Amsterdam and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.

[3 ] Hospital Universitari Vall d'Hebron, Barcelona, Spain; Investigació i Recerca en Atenció Primària Jordi Gol, Barcelona, Spain.

[4 ] Heart of England Foundation Trust, Birmingham, UK.

[5 ] Centro Hospitalar de Vila Nova Gaia/Espinho, Vila Nova Gaia, Portugal; EpiUnit, Institute of Public Health, Medical School Porto University, Porto, Portugal.

[6 ] L Spallanzani National Institute for Infectious Diseases, Rome, Italy.

[7 ] Heart of England Foundation Trust, Birmingham, UK; Queen Mary University, London, UK.

[8 ] St Pieter University Medical Centre, Brussels, Belgium.

[9 ] Marius-Nasta-Institut, Bucharest, Romania.

[10 ] Azienda Ospedaliera di Valtellina e Valchiavenna E Morelli Hospital, Reference Hospital for MDR and HIV-TB, Sondalo, Italy; Department of Infection, Barts Health NHS Trust, London, UK.

[11 ] National Institute for Health Development, Tallinn, Estonia.

[12 ] Division of Clinical Infectious Diseases and German Center for Infection Research Tuberculosis Unit, Research Center Borstel, Borstel, Germany; Department of Medicine, University of Namibia School of Medicine, Windhoek, Namibia; Department of Medicine, Karolinska Institute, Stockholm, Sweden.

Article

DOI: 10.5588/ijtld.15.0274

PubMed ID: 26614196

SO-VID: 0dd11060-1aaa-42ce-8a3c-3a649b0eafb8

History

Data availability:

Comments

Comment on this article

scite_

Cited by 13

See all cited by